Contrast-enhanced computed tomography evaluation of hepatic metastases in breast cancer patients before and after cytotoxic chemotherapy or targeted therapy

Canadian Association of Radiologists Journal

Volumn 66, Issue 4, 2015, Pages 356-362

  He, Hongying ^a,b   Cai, Chunyan ^b   Charnsangavej, Chusilp ^a   Theriault, Richard L ^a   Green, Marjorie ^a   Quraishi, Mohammad A ^a   Yang, Wei T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Computed tomography evaluation; Hepatic metastases; Targeted therapy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG TARGETING; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; AGED; BREAST NEOPLASMS; COMPARATIVE STUDY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SECONDARY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; SURVIVAL ANALYSIS; TAMOXIFEN; TOMOGRAPHY, SPIRAL COMPUTED; TRASTUZUMAB;

EID: 84959932859     PISSN: 08465371     EISSN: 14882361     Source Type: Journal    
DOI: 10.1016/j.carj.2015.03.005     Document Type: Article

References (17)

1. M.J. Higgins, and A.C. Wolff Therapeutic options in the management of metastatic breast cancer Oncology 22 2008 614 623
2. A. Hamilton, and G. Hortobagyi Chemotherapy: what progress in the last 5 years? J Clin Oncol 23 2005 1760 1775
3. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
4. B. Escudier, T. Eisen, W.M. Stadler, and et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
5. H. Choi, C. Charnsangavej, S. de Castro Faria, and et al. CT Evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol 183 2004 1619 1628
6. A.D. Smith, M.L. Lieber, and S.N. Shah Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT AJR Am J Roentgenol 194 2010 157 165
7. A.D. Smith, S.N. Shah, B.I. Rini, and et al. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy AJR Am J Roentgenol 194 2010 1470 1478
8. P.D. Nathan, A. Vinayan, D. Scott, and et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies Cancer Biol Ther 9 2010 15 19
9. Y.S. Chun, J. Vauthey, P. Boonsirkamehai, and et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases JAMA 302 2009 2338 2344
10. A.S. Coates, A. Keshaviah, B. Thurlimann, and et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 2007 486 492
11. J.F. Forbes, J. Cuzick, A. Buzdar, and et al. Effect of Anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 2008 45 53
12. P.E. Goss, J.N. Ingle, S. Martino, and et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada clinical trials group MA 17. J Clin Oncol 25 2007 2006 2011
13. D.J. Slamon, B. Leyland-Jones, S. Shak, and et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
14. S.H. Park, W.K. Moon, N. Cho, and et al. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer Eur Radiol 22 2012 18 25
15. J. Dose Schwarz, M. Bader, L. Jenicke, and et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med 46 2005 1144 1150
16. T. Bauerle, S. Bartling, A. Schmit-Graff, and et al. Imaging anti-angiogenic treatment response with DCE-VCT, DCE MRI and DWI in an animal model of breast cancer bone metastasis Eur J Radiol 73 2010 280 287
17. N. Avril, S. Sassen, and R. Roylance Response to therapy in breast cancer J Nucl Med 50 2009 55S 63S